Study #2021-0409
A Phase 2 Trial of Atezolizumab and Cabozantinib in Adolescents and Young Adults with Recurrent/metastatic Osteosarcoma (TACOS)
MD Anderson Study Status
Enrolling
Treatment Agent
Atezolizumab, Cabozantinib
Description
This phase II trial studies the effect of atezolizumab and cabozantinib in treating adolescents and young adults with osteosarcoma that has come back (recurrent) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab and cabozantinib may help to control the osteosarcoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Locally Advanced Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Unresectable Osteosarcoma
Study phase:
Phase II
Physician name:
John Livingston
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.